Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

Trifecta Approach Important In Prostate Cancer Treatment

April 21, 2010 By AxoGen, Inc.

Three is a very important number to Dr. David Samadi, Chief of Robotics and Minimally Invasive Surgery at The Mount Sinai Medical Center. Considered a mystical number, Samadi has incorporated this number in his robotic prostatectomy practice. Having performed 3,000 successful prostate cancer treatments in his work, Samadi’s experience is unparalleled. Thanks to three fellowships, he is not only an accomplished robotic surgeon, he is also expertly trained in open and laparoscopic surgery. Samadi refers to himself as "three surgeons in one head," which is crucial in surgery, if he needed to switch from one type of surgery to another.

Prostate Cancer Treatment Options
When determining prostate cancer treatment for his patients, Dr. Samadi uses a three-pronged approach, taking into consideration their prostate specific antigen (PSA) level, digital rectal exam (DRE) and Gleason scores. This information is used as a baseline monitor, along with other risk factors such as lifestyle and family history, to help successfully treat this disease.

Currently, the most popular treatment options for prostate cancer are radiation, active surveillance and prostatectomy. Radiation uses high-energy rays or seeds to kill cancer cells. It is ideal for low-grade, prostate-confined cancer and recurrent cancer cases. Active surveillance, also known as "watchful waiting," means waiting until the cancer exhibits symptoms before starting treatment. In other cases, it involves closely monitoring the patient’s tests, exams and ultrasounds to ascertain the cancer’s growth. The third option is a radical prostatectomy, whereby the entire prostate gland is removed, which can be done traditionally (via open surgery), laparoscopically, or robotically.

In choosing a treatment, understandably Dr. Samadi stands behind the viability of a radical prostatectomy. It is, in Samadi’s opinion, the "gold standard" for completely eliminating prostate cancer that is organ-confined. Understandably, he advocates a robotic prostatectomy, via the da Vinci robot, as the most effective way of treating prostate cancer. "It is only by removing the prostate that I can ascertain three things: if the cancer is organ-contained, the type of cancer, and the stage of the cancer," explained Samadi.

The "Triple Play" Philosophy
In keeping with his "triple play philosophy," Dr. Samadi believes that with the experience of open prostate surgery and laparoscopic prostatectomy, robotic surgery can offer his patients the best cure (with post-operative long-term PSA levels undetectable), retention of sexual function, and continence (see charts). "All three factors are equally important to my patients, and my experience with robotic surgery has consistently provided these to them," continued Samadi.

Dr. Samadi envisions promising advancements in the arena of prostate cancer research. He cites the possibility of gene therapy, whereby prostate cancer cells are infected with genes that prevent them from multiplying. Another hopeful treatment includes immunotherapy, which stimulates the body’s own immune system to attack cancer cells. And finally, there are many potential vaccines being researched to prevent prostate cancer from developing in the first place.

"Choosing robotic surgery is a no-brainer. Choosing the right surgeon who performs a large volume of these cases and is also a trained oncologist is most important," says Dr. Samadi. "I have increased visibility, magnification, and dexterity with no tremors. The patient’s time in surgery is reduced to 1-2 hours. The incisions are smaller, with minimal blood loss. They are discharged within 24 hours. Recovery is faster and side effects are practically eliminated." Samadi is confident in his trifecta approach to prostate cancer and robotic surgery as the most effective treatment option available.

Related Articles Read More >

Lazurite ArthroFree wireless surgical camera system Minnetronix Medical
How Minnetronix Medical helped Lazurite with its wireless surgical camera
Medtronic Hugo robot-assisted surgery system
The road to a robot: Medtronic’s development process for its Hugo RAS system
A portrait of Stryker executive Siddarth Satish
How Stryker includes users for product design in the digital age
A portrait of Stryker executive Tracy Robertson
Stryker leaders talk medtech trends at DeviceTalks Boston: ‘If you’re slow, you’re going to lose’

DeviceTalks Weekly.

May 13, 2022
Our Pre-Post-DeviceTalks Boston episode, also MedtronicTalks replay with Gastro CMO Austin Chiang
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech